Talaris Therapeutics Inc (TALS) 銘柄情報

Relative buying vol up 120Xs,one of highest in mkt today.ave vol up 28Xs

Up 160% this year,6 month trend now revealed why,merger with private co.insiders can buy now it’s revealed,could go up faster now too,how this is not found yet is beyond me

Book pps 3.87,analysts target 7,50,GOLDEN CROSS!!,confirms bullish trend to continue

210M cash coming,strong balance sheet.3 clinical trials,all phase 2

Merger,900k short,shares to short dropping, 35%today,going to run out today at this rate

NEWS
TALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)-- Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Talaris Therapeutics, Inc. (NASDAQ: TALS) and Tourmaline Bio, Inc. is fair to Talaris shareholders. Talaris shareholders immediately prior to the proposed transaction are expected to own approximately 21.3% of the combined company.

Halper Sadeh encourages Talaris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Talaris and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Talaris shareholders; and (2) disclose all material information necessary for Talaris shareholders to adequately assess and value the merger consideration. On behalf of Talaris shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Talaris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20230622642074r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20230622642074/en/

Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Source: Halper Sadeh LLC

© Copyright Business Wire 2023

“2:27p ET 10/20/2022 - Benzinga
HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space
Mentioned: TALS
HC Wainwright initiated coverage on Talaris Therapeutics Inc (NASDAQ: TALS) with a Buy rating and a price target of $18.
Talaris leverages its novel 'facilitated' allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform for solid organ transplantation, autoimmune diseases, and severe blood, immune and metabolic disorders.
The facilitated Allo-HSCT attempts to unify two immune systems into one (chimerism) such that both the donor and recipient immune cells function harmoniously in the recipient.
Earlier today, Talaris received a report of a patient death, which triggered a pre-specified, temporary stopping requirement and review by the FREEDOM-1 Data Monitoring Committee (DMC).
The analyst views the attributes of Talaris' technology as unprecedented in the cell therapy space and holding potential for broad market adoption in kidney transplants and other indications.
If approved by the end of 2026, HC Wainwright expects FCR001 could achieve over $1 billion in sales in the U.S. by 2030, with significant room for upside growth in the succeeding years.
The analyst also notes investor concerns regarding treatment-related GvHD incidence and writes that physicians perceive mild Grade 2 GvHD as a recurring event in kidney transplant patients.
Price Action: TALS shares are down 44.63% at $1.34 on the last check Thursday.
Latest Ratings for TALS DateFirmActionFromTo

Nov 2021SVB LeerinkMaintainsOutperform Jun 2021Morgan StanleyInitiates Coverage OnOverweight Jun 2021GuggenheimInitiates Coverage OnBuy

View More Analyst Ratings for TALS

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”